Business
ORIC Pharmaceuticals Announces Multiple Presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting
ORIC-944 preclinical poster presentation to highlight comprehensive biomarker strategy for ongoing Phase 1 trial in metastatic prostate cancer PLK4 poster
About this update from Oric Pharmaceuticals, Inc.
[{"type":"text","content":"ORIC-944 preclinical poster presentation to highlight comprehensive biomarker strategy for ongoing Phase 1 trial in metastatic prostate cancer PLK4 poster presentation to spotlight the high selectivity required for synthetic lethality in breast cancer models SOUTH SAN FRANCISCO and SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that two abstracts have been accepted for poster presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting taking place April 14-19, 2023, in Orlando, FL. The presentations will highlight: preclinical biomarker results for ORIC-944, a potent and selective allosteric inhibitor of PRC2 currently in Phase 1 for patients with metastatic prostate cancer; andpreclinical data from ORIC’s selective PLK4 inhibitor discovery program Details of the presentations are as follows: Title: Biomarker strategy for a phase 1 study of ORIC-944, a potent and selective allosteric PRC2 inhibitor, in patients with metastaticSession Category: Experimental and Molecular TherapeuticsSession Title: Pharmacokinetics, Pharmacodynamics, and MolecularPharmacologySession Date & Time: Monday, April 17, 2023, 1:30 p.m. - 5:00 p.m. ETLocation: Poster Section 18 Abstract Number: 2791 Abstract HighlightsORIC-944 is a potent, highly selective allosteric small molecule inhibitor of PRC2, the complex which tri-methylates histone H3 and lysine 27 (H3K27me3) leading to transcriptionally silenced genes. Preclinical pharmacology studies in mice showed that H3K27me3 levels significantly decreased in response to ORIC-944 in a dose- and time-dependent manner, in epidermis, monocytes, and plasma. Assays included immunohistochemistry, alphaLISA, and cell-free nucleosomal bead-based sandwich immunoassay. Additionally, putative PRC2 target genes were identified in xenograft tumors profiled by RNA-sequencing and H3K27me3 chromatin immunoprecipitation sequencing. The establishment of these assays represent a comprehensive biomarker strategy of target engagement and pharmacodynamic biomarkers for use in the ongoing Phase 1 trial of ORIC-944 in patients with metastatic prostate cancer. Title: Selective PLK4 inhibition demonstrates synthetic lethality in TRI...